Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of ACE910 (emicizumab) in hemophilia A patients
jRCT2080222149Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2013
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of emicizumab in hemophilia A, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Long-term safety of emicizumab. Started Jul 2013; status: completed.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCT2080222149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222149.